Back to Journals » International Journal of Nanomedicine » Volume 13 » T-NANO 2014 Abstracts

In vitro cytotoxicity of GO–DOx on FaDu squamous carcinoma cell lines

Authors Singh M, Gupta P, Baronia R, Singh P, Karuppiah S, Shanker R, Dwivedi PD, Singh SP

Received 17 October 2016

Accepted for publication 27 January 2017

Published 15 March 2018 Volume 2018:13(T-NANO 2014 Abstracts) Pages 107—111

DOI https://doi.org/10.2147/IJN.S124891

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Lei Yang


Manjri Singh,1 Parul Gupta,2 Richa Baronia,1 Priti Singh,1 Stalin Karuppiah,1 Rishi Shankar,3 Premendra D Dwivedi,2 Surinder P Singh1

1
CSIR-National Physical Laboratory, New Delhi, 2CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, 3Institute of Life Sciences, Ahmedabad University, Ahmedabad, Gujarat, India


Abstract: We have synthesized graphene oxide (GO) nanosheets using modified Hummer’s method and conjugated it with doxorubicin (DOx), an anticancer drug. Drug release kinetics from GO–DOx conjugate indicated the drug release at acidic pH. MTT assay performed on FaDu hypopharyngeal cancer cell lines revealed that the GO–DOx nanoconjugate inhibited cell proliferation more efficiently compared with pure DOx. Preliminary results indicate the potential of designed GO–DOx drug conjugate for head and neck cancer.

Keywords: graphene oxide, doxorubicin, nanomedicine, head and neck cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]